2010
DOI: 10.1093/protein/gzq037
|View full text |Cite
|
Sign up to set email alerts
|

Structure-based engineering of a monoclonal antibody for improved solubility

Abstract: Protein aggregation is of great concern to pharmaceutical formulations and has been implicated in several diseases. We engineered an anti-IL-13 monoclonal antibody CNTO607 for improved solubility. Three structure-based engineering approaches were employed in this study: (i) modifying the isoelectric point (pI), (ii) decreasing the overall surface hydrophobicity and (iii) re-introducing an N-linked carbohydrate moiety within a complementarity-determining region (CDR) sequence. A mutant was identified with a mod… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
2

Citation Types

9
186
0

Year Published

2014
2014
2018
2018

Publication Types

Select...
5
3

Relationship

0
8

Authors

Journals

citations
Cited by 170 publications
(195 citation statements)
references
References 60 publications
(74 reference statements)
9
186
0
Order By: Relevance
“…The involvement of CDR regions, including specific aromatic/hydrophobic residues, in RSA of antibodies has been reported in previous studies with other antibodies. 16,66,67 More specifically with mAb-C, LC 36-71 and HC 35-60, which span CDR2L and CDR2H, respectively, showed significant decreases in hydrogen exchange under RSA-promoting conditions (Fig. 7).…”
Section: Discussionmentioning
confidence: 96%
See 1 more Smart Citation
“…The involvement of CDR regions, including specific aromatic/hydrophobic residues, in RSA of antibodies has been reported in previous studies with other antibodies. 16,66,67 More specifically with mAb-C, LC 36-71 and HC 35-60, which span CDR2L and CDR2H, respectively, showed significant decreases in hydrogen exchange under RSA-promoting conditions (Fig. 7).…”
Section: Discussionmentioning
confidence: 96%
“…68 In another study, substitution of aromatic residues with non-aromatic amino acids (F99A, W100A) in the CDR3H region of the antibody caused a considerable decrease in RSA and an increase in protein solubility. 16,67 However, Fab-Fab interactions are not necessarily always responsible for such interactions between antibody molecules. For example, Nishi et al reported Fc-mediated RSA of an antibody under low ionic strength solution conditions.…”
Section: Discussionmentioning
confidence: 99%
“…Antigen bound co-crystals are also very useful for determining mutants that are more likely to retain target binding while optimizing solubility. 7 …”
Section: Discussionmentioning
confidence: 99%
“…2–4 Successful efforts have also been made to use rational design to reduce aggregation and improve solubility by mutating hydrophobic surface regions derived from a crystal structure. 57 …”
Section: Introductionmentioning
confidence: 99%
“…[2][3][4] To avoid such setbacks, risk mitigation strategies increasingly center around "Quality-by-Design" (QbD) approaches, which consider developability-related issues early in the drug discovery phase and involve rationally engineering antibodies toward favorable Chemistry, Manufacturing and Control (CMC) and pharmacokinetics (PK) properties. [5][6][7] Choosing molecules that exhibit low intrinsic immunogenicity and that are robust against the formation of immunogenic degradation products can also reduce safety risks. However, the large number of different antibodies typically considered in early projects, and the small amount of each antibody that is typically available, precludes extensive experimental characterization and determination of CMC properties such as yield, chemical and physical stability.…”
Section: Introductionmentioning
confidence: 99%